Boston Therapeutics Inc

Boston Therapeutics — Investor Presentation (November 2021)

21 slides from Boston Therapeutics's investor presentation, Nov 5, 2021

  1. Slide 1: Nanomix November 2021

    Slide 1: Nanomix November 2021

    “= nanomix November 2021

  2. Slide 2: Safe Harbor Statement

    Slide 2: Safe Harbor Statement

    Safe Harbor Statement Statements contained in this presentation that are not historical facts may be forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 . Forward - looking statements include statements regarding the intent, belief or current expec

  3. Slide 3: Nanomix Delivers On the Promise of Point of Care Testing

    Slide 3: Nanomix Delivers On the Promise of Point of Care Testing

    Nanomix Delivers On the Promise of Point of Care Testing • Leader in decentralized testing – large, fast - growing market • Need for decentralized testing is reinforced by COVID - 19 experience • Most Advanced Mobile Diagnostic System • One instrument for many different tests • Lab quality results i

  4. Slide 4: Publicly Listed via Reverse Merger

    Slide 4: Publicly Listed via Reverse Merger

    Publicly Listed via Reverse Merger • Reverse merger with Boston Therapeutics (OTCQB:BTHE) completed June 2021 – Name and Ticker Symbol change in process – 54.6 million shares (fully diluted) post reverse split in process • Convertible Equity financing completed post merger – $8.4M Notes placement; a

  5. Slide 5: Point-of-Care Testing (POCT) – A $20B Market Ripe for Disruption

    Slide 5: Point-of-Care Testing (POCT) – A $20B Market Ripe for Disruption

    Point - of - Care Testing (POCT) – A $20B Market Ripe for Disruption 5

  6. Slide 6: Decentralized Diagnostic Testing Venues

    Slide 6: Decentralized Diagnostic Testing Venues

    The Institute of Medicine (IOM) estimates that $750 billion — 30% of the U.S. annual health care budget — is wasted on unnecessary services, inefficient delivery, excessive administrative costs and prevention failures …studies have reported that up to 34% of Medicare patients transported by EMS to a

  7. Slide 7: The Nanomix system is based on proprietary, innovative technology

    Slide 7: The Nanomix system is based on proprietary, innovative technology

    The Nanomix system is based on proprietary, innovative technology providing significant advantages in accuracy, portability and cost 7 • Advantages over traditional optical techniques • Multiplex and multiple assay techniques • Inexpensive, sensitive sensors • Designed for use in or outside of tradi

  8. Slide 8: A Complete Mobile Immunoassay Diagnostic System

    Slide 8: A Complete Mobile Immunoassay Diagnostic System

    ACCURATE FAST MOBILE CONNECTED Proprietary sensor technology brings immunoassay sensitivity and specificity to the POC Microfluidics technology delivers reproducibility and a quick 10 – 15 minutes sample - to - answer Rugged design and menu driven software enables use in mobile settings with limited

  9. Slide 9: Intuitive Menu-Driven Testing

    Slide 9: Intuitive Menu-Driven Testing

    2 Load patient sample 4 Results Bluetooth via QR code 1 Scan test cartridge 3 Insert test cartridge and push ‘go’ Intuitive Menu - Driven Testing 9

  10. Slide 10: Focus on high-value markets: Rapid Tests for Improved Patient Outcomes

    Slide 10: Focus on high-value markets: Rapid Tests for Improved Patient Outcomes

    Focus on high - value markets 10 Rapid Tests for Improved Patient Outcomes Sepsis AKI TBI Stroke Time to Result Mobility Accuracy

  11. Slide 11: S1 assay panel is first element of Nanomix strategy

    Slide 11: S1 assay panel is first element of Nanomix strategy

    S1 assay panel is first element of Nanomix strategy: target assays where high accuracy and immediacy are of great value in patient care . 11

  12. Slide 12: Critical Infections: A Global Health Challenge

    Slide 12: Critical Infections: A Global Health Challenge

    1. Rudd, et al. Lancet. 2020; 395: 200 - 11 2. Markwart, et al. Intensive Care Med. 2020; 46(8): 1536 - 51 3. Prescott, H. C., Sjoding , M. W. & Iwashyna , T. J. Diagnoses of early and late readmissions Ann. Am. Thorac . Soc. 11 , 1091 – 1100 (2014). 4. Heublein , et al. J Infect. 2017; 74(2): 107 -

  13. Slide 13: Critical Infection Assay Panel (S1) Unique Mobile POC Solution

    Slide 13: Critical Infection Assay Panel (S1) Unique Mobile POC Solution

    Critical Infection Assay Panel (S1) 13 Unique Mobile POC Solution Differentiated Credible Customer Ready • Only POC multiplexed panel for PCT, CRP, & LAC • Results in 11 minutes • Lab quality results • Proven in Multi - center clinical trials • Consistent with current clinical information • CE Marke

  14. Slide 14: S1 Assay Panel Addresses Major Needs

    Slide 14: S1 Assay Panel Addresses Major Needs

    S1 Assay Panel Addresses Major Needs 14 Clinical Impact Reduce 30 - day mortality Reduce antibiotic exposure Reduce healthcare acquired complications Improve transition of care decisions Timely host response diagnostics improve patient outcomes Disease • Pneumonia • Sepsis • COPD exacerbation • Crit

  15. Slide 15: S1 Assay Panel – Large Addressable Market

    Slide 15: S1 Assay Panel – Large Addressable Market

    S1 Assay Panel – Large Addressable Market 15 $627M 9.5% CAGR Sepsis $446M 5.1% CAGR Pneumonia Worldwide Diagnostic Market Nanomix Target Market Emergency Departments Critical Care Access Community Hospitals Extended Care Facilities Nanomix Market Opportunity $ 200M

  16. Slide 16: Broadening the number of tests expands TAM

    Slide 16: Broadening the number of tests expands TAM

    Time Sensitive – Sepsis, Stroke, TBI, AKI, Cardiac Chronic/Acute Diseases Sexual Health Infectious Disease Wellness Menu of <15 tests $5B TAM 50 tests $15B TAM +150 tests + $38B TAM Broadening the number of tests expands TAM... 16 Time Sensitive – Sepsis, Stroke, TBI, AKI, Cardiac Chronic/Acute Dise

  17. Slide 17: Nanomix go to market via established distribution partners

    Slide 17: Nanomix go to market via established distribution partners

    National distributor(s) for North America (TBD) Regional or Country distributors Nanomix go to market via established distribution partners 17 Customer Acquisition Leverage existing relationships between distributor and end - user customers. Access large buyers through existing buying contracts Cust

  18. Slide 18: Business model

    Slide 18: Business model

    Business model 18 Revenue and margin driven by consumable cartridge sales ELAB ANALYZER • Analyzer runs multiple cartridge types RETAIL PRICE $8,000 MARGIN TARGET ~25% CARTRIDGES • Primary Source of Revenue • À la carte pricing based on specific tests • Single use RETAIL PRICE $10 - 50+ MARGIN TARGE

  19. Slide 19: Innovative Diagnostic Platforms Create Value

    Slide 19: Innovative Diagnostic Platforms Create Value

    Innovative Diagnostic Platforms Create Value Global IVD market is $75B Market participants acquire new technology to build market presence Nanomix mobile diagnostic system is the next healthcare technology frontier. ALERE ABBOTT POC $5.3B CEPHEID (MDx) DANAHER $3.9B ABAXIS (VET) ZOETIS $1.8B INNOVAT

  20. Slide 20: Management

    Slide 20: Management

    Management 20 David Ludvigson ; President and CEO Mr. Ludvigson is a financial and operating executive, and entrepreneur, with over 35 years of international experience in lif e s ciences and technology companies including IDEC Pharmaceuticals, Matrix Pharmaceutical, Nanogen , and MIPS Computer Syst

  21. Slide 21: Nanomix

    Slide 21: Nanomix

    “= nanomix

Source: SEC EDGAR · 8-K filed Nov 5, 2021

More decks from Boston Therapeutics Inc